Date: 2011-10-06
Type of information: Licensing agreement
Compound: non-catalytic site integrase inhibitors (NCINIs) for HIV
Company: Boehringer Ingelheim (Germany) Gilead (USA)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease: HIV-AIDS
Details: Boehringer Ingelheim and Gilead Sciences, have entered into a licensing agreement, under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV. This includes the lead compound BI 224436, which has been evaluated in a Phase 1a dose-escalation study to assess bioavailability and pharmacokinetics in healthy volunteers.
Financial terms: Under the terms of the agreement, Gilead will pay Boehringer Ingelheim an upfront payment. Boehringer Ingelheim could receive additional payments based upon the achievement of certain development, regulatory and commercial milestones, as well as royalties on future net sales.
Latest news:
